Laidlaw initiated coverage on IN8bio with a new price target
$INAB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Laidlaw initiated coverage of IN8bio with a rating of Buy and set a new price target of $7.50
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/18/2024 | $7.50 | Buy | Laidlaw |
| 8/30/2022 | $14.00 | Buy | H.C. Wainwright |
| 1/24/2022 | $19.00 → $9.00 | Buy | B. Riley Securities |
| 8/24/2021 | $12.00 | Buy | Mizuho |
| 8/23/2021 | $19.00 | Buy | B. Riley Securities |
EFFECT - IN8BIO, INC. (0001740279) (Filer)
424B3 - IN8BIO, INC. (0001740279) (Filer)
10-Q - IN8BIO, INC. (0001740279) (Filer)
4 - IN8BIO, INC. (0001740279) (Issuer)
4 - IN8BIO, INC. (0001740279) (Issuer)
4 - IN8BIO, INC. (0001740279) (Issuer)
Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session following fourth-quarter results. AMMO reported a fourth-quarter profit of 1 cent per share, compared to market expectations for a loss of 1 cent per share. The company reported quarterly sales of $40.42 million topping estimates of $37.90 million, according to data from Benzinga Pro. AMMO shares dipped 19.1% to $2.0306 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) shares jumped 345% to $6.06. SRIVARU Holding Limited (NASDAQ:SVMH) gained 150% to $0.3852 after the company announced it will begin accepting paid reserva
Gainers Cyclerion Therapeutics (NASDAQ:CYCN) shares moved upwards by 37.4% to $2.9 during Friday's regular session. The market value of their outstanding shares is at $7.2 million. CNS Pharma (NASDAQ:CNSP) stock rose 35.86% to $4.92. The market value of their outstanding shares is at $1.9 million. Longeveron (NASDAQ:LGVN) shares moved upwards by 23.23% to $3.31. The market value of their outstanding shares is at $21.0 million. iSpecimen (NASDAQ:ISPC) stock moved upwards by 19.44% to $0.49. The market value of their outstanding shares is at $4.8 million. Scinai Immunotherapeutics (NASDAQ:SCNI) stock rose 17.8% to $3.32. The market value of their outstanding shares is at $1.9 million. Di
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points on Friday. The Dow traded down 0.63% to 38,403.11 while the NASDAQ fell 0.07% to 17,655.10. The S&P 500 also fell, dropping, 0.37% to 5,413.41 . Check This Out: Top 2 Materials Stocks That May Collapse This Quarter Leading and Lagging SectorsCommunication services shares jumped by 0.4% on Friday. In trading on Friday, industrials shares fell by 2.1%. Top Headline The University of Michigan consumer sentiment declined for a third consecutive month to a reading of 65.6 in June, notching the lowest level since November, compared to 69.1 in May and down from market estimates
SC 13D/A - IN8BIO, INC. (0001740279) (Subject)
SC 13G - IN8BIO, INC. (0001740279) (Subject)
SC 13G/A - IN8BIO, INC. (0001740279) (Subject)
Internationally recognized immuno-oncology and cell therapy executive with 20 years of experience in innovative immunotherapies for solid and hematological cancersBoard-Certified physician-scientist with deep experience at leading organizations such as Bristol Myers Squibb, Iovance Biotherapeutics, the National Cancer Institute (NCI), Goldman Sachs and most recently CARGO Therapeutics NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the appointment of Corinne Epperly, MD, MPH, to its Board of Directors. "Dr. Epperly brings an incredible range of ex
Dr. Jeremy Graff spent 17 years at Eli Lilly and Company, where he built and led the translational oncology group, supporting and advancing 31 clinical assets in Eli Lilly's oncology portfolioHe is a highly respected industry leader in oncology with a track record of success in advancing multiple novel anti-cancer compounds into and through the clinic and has been instrumental in garnering the approval of several oncology products NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, is pleased to announce the appointment of Jeremy Graff, Ph.D., to its Board of Directors
NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced it has appointed Michael R. Bishop, M.D., F.A.C.P., F.A.S.C.O., to its Scientific Advisory Board (SAB). Dr. Bishop is Director, Hematopoietic Cellular Therapy Program, and Director of the David and Etta Jonas Center for Cellular Therapy, and Professor of Medicine at the University of Chicago. He joins the other world-renowned experts in oncology, cellular immunotherapy and immunology on IN8bio's SAB who provide expertise, contribute insights and advise the Comp
Laidlaw initiated coverage of IN8bio with a rating of Buy and set a new price target of $7.50
H.C. Wainwright initiated coverage of IN8bio with a rating of Buy and set a new price target of $14.00
B. Riley Securities reiterated coverage of IN8bio with a rating of Buy and set a new price target of $9.00 from $19.00 previously
Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future INB-100 registrational trialINB-100 trial currently expanding enrollment up to approximately 25 patients at the recommended Phase 2 dose (RP2D) along with the potential to add additional centers and a prospective parallel observational cohort as a controlClosed private placement for net proceeds of $11.6 Million in October 2024 extending cash runway through 2025 NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company developi
Plenary Oral Presentation at SNO will provide latest clinical trial results from the previously enrolled INB-200 studies of autologous gamma-delta T cells for newly diagnosed glioblastoma (GBM) NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming plenary oral presentation at the 29th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), being hosted November 21 – 24, 2024 in Houston, TX. IN8bio will provide longer-term follow-up and additional data demonstrating the activity of its DRI gamma-delta T cell approach in solid tumors
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being hosted December 7 – 10, 2024 in San Diego, CA. Details for the ASH 2024 presentation are as follows: Title: INB-100: Pilot Study of Donor Derived, ex-vivo Expanded/Activated Gamma-Delta T cell Infusion Following Haploidentical Hematopoietic Stem-Cell Transplantation and Post-Transplant Cyclophosphamide Presenter: Joseph McGuirk, DO, The University of Kansas Cancer Center Abstract #: 4823 Se
100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia (AML) patients who had previously failed multiple lines of therapy, including CAR-T. Data continue to show long-term in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration, demonstrating first-ever durable persistence and expansion of an allogeneic cellular therapy. The Company will host a conference call at 4:15 pm ET. Use this link to participate. A listen-only version of the webcast is available here. NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clini
Durable complete remission (CR) achieved in 100% of treated patients, including high-risk and relapsed acute myeloid leukemia (AML) patients and those who had failed multiple prior lines of therapy, including CAR-T.All trial participants remain alive and relapse free as of last assessment, and six patients have been relapse free for over one year.New data shows long-term in-vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration of INB-100, demonstrating the first-ever durable persistence of an allogeneic cellular therapy.Data to be presented today (abstract: 4853) at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
Event will follow the presentation of INB-100 data in patients with hematologic malignancies at the American Society of Hematology (ASH) 65th Annual Meeting & Exposition on the evening of December 11, 2023IN8bio's management team will be joined by clinical thought leader Michael Bishop, MD, Director of the David and Etta Jonas Center for Cellular Therapy at The University of ChicagoThe live webcast can be accessed here NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the Company will host a conference call on Tuesday, December 12, 2023 at 8:30 am ET